Stryker reported $6.5B in revenue (+7.6% YoY), compared with a +7.2% median across covered Health Care peers. Of 1 tracked management expectations, 1 were consistent with later reports and 0 were contradicted. 1 insider sale recorded.
Notable trades by executives and major shareholders from November 7 to November 13: open-market purchases, sales, and proposed sales. Disclosures do not indicate how an insider views the company and are not a recommendation to buy or sell.
Компанія Stryker Corporation оприлюднила фінансові результати за третій квартал 2026 року та подала автоматичну заяву на реєстрацію цінних паперів. Квартальна виручка компанії зросла до 6,52 млрд USD, при цьому чистий прибуток скоротився на 12,3% у річному порівнянні.
From October 31 to November 6, company executives and directors reported share transactions. This review covers market operations and plans to sell securities. Such disclosures are a technical requirement and do not allow for an assessment of insider sentiment or future company results.
Stryker Corporation released its third quarter 2026 results on October 29, 2026. The company also announced that its board of directors approved a $3 billion increase to its existing share repurchase program, in addition to the $1.0 billion spent on repurchases during the third quarter.
Stryker Corporation said Kevin A. Lobo will resign as chief executive officer on Dec. 31, 2026 and will become executive chair of the board on Jan. 1, 2027, while current president and chief operating officer Spencer S. Stiles will become the new chief executive officer and president.
STRYKER CORP: 12 recorded developments from 4 official sources in 2026-10.
2026-10-06: Stryker Corporation announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the Board of Directors of the Company (the “Board”), effective January 1, Source
2026-10-06: Kevin Lobo will transition to Executive Chair of the Board of Directors and Spencer Stiles appointed Chief Executive Officer, effective January 1, 2027Source
2026-10-06: Nick Mead serves as Vice President of Investor Relations at Stryker, contactable at 269-385-2600 or nick.mead@stryker.com for investor inquiries.Source
2026-10-06: Kim Montagnino serves as Vice President and Chief Communications Officer at Stryker, contactable at 269-385-2600 or kim.montagnino@stryker.com for media inquiries.Source
2026-10-06: On October 5, 2026, the Company entered into a letter agreement with Mr. Stiles (the “Letter Agreement”) establishing his compensation as CEO of the Company, effective as of January 1, 2027.Source
2026-10-06: Mr. Stiles, age 50, has served as President and Chief Operating Officer of the Company since January 2026.Source
2026-10-06: Prior to that, he served as Group President, Orthopaedics, from 2019.Source
2026-10-06: Throughout his 27-year career at the Company, he has held leadership roles across Orthopaedics as well as MedSurg and Neurotechnology and has overseen international regions and key supporting functions.Source
2026-10-06: Mr. Stiles graduated from Miami University with a bachelor’s degree in business and received his MBA from the University of Nebraska.Source
2026-10-06: Mr. Lobo’s annual base salary, annual bonus target and employee benefit plan eligibility will remain unchanged following the CEO Transition, but he will not be eligible to receive any new stock awards while serving as Executive Chair of the Board.Source
2026-10-29: Stryker Corporation issued a press release on October 29, 2026 announcing its third quarter 2026 operating results.Source
2026-10-29: In the first quarter of 2026, Stryker announced a change in its organizational structure, combining Orthopaedic Instruments and Other Orthopaedics into a new Ortho Tech business, and combining Neuro Cranial and Enabling Technologies into the Instruments business.Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Key figures
From the 10-Q for the period ended September 30, 2026, filed October 30, 2026. SEC
Latest
Earlier
Change
Revenue quarter
$6.5B
$6.1B
+7.6%
Operating income quarter
$1B
$1.1B
-8.9%
Net income quarter
$753M
$859M
-12.3%
Diluted EPS quarter
$1.96
$2.22
-11.7%
Dividends per share quarter
$0.88
$0.84
+4.8%
Operating cash flow year to date
$3.3B
$2.9B
+13.9%
Cash and cash equivalents balance
$3.3B
$4B
-18.4%
Long-term debt balance
$14.2B
$14.9B
-4.6%
Next results expected around January 29, 2027 (estimate: the quarter ending about December 30, 2026 plus the 30 days the last report took). The company announces the actual date.
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
Bottom row: operating margin (operating income divided by revenue). Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
How expectations played out
1 of 1 expectation checked against later reports
1 confirmed
Mostly AI assessments, provisional; an editor's decision replaces them. Not a rating of the shares.
Checked against later reports
The company expects full year 2026 organic net sales growth in the range of 6.5% to 7.0% and adjusted net earnings per diluted share in the range of $14.80 to $14.90.
Said October 29, 2026 · Period named: full year 2026 · Source · Our article
AI assessment, provisional later reports are consistent with it (as of November 6, 2026) · Later article
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
Date
Event
Filing
November 9, 2026
Director or officer departure or appointment (8-K item 5.02)
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.